Nuvectis Pharma to Present NXP900 at 2024 AACR-NCI-EORTC Symposium

Nuvectis Pharma, Inc., a company based in Fort Lee, NJ, has announced its upcoming participation in the 2024 AACR-NCI-EORTC conference on Molecular Targets and Cancer Therapeutics, which will be held from October 23-25, 2024 in Barcelona, Spain. Nuvectis Pharma is a clinical-stage biopharmaceutical company that focuses on developing innovative precision medicines for treating serious conditions in oncology, particularly those with unmet medical needs.

During the conference, Nuvectis will present scientific findings on their novel cancer drug candidate, NXP900. The presentations will highlight the drug's potential and its current phase of development. NXP900 is an oral small molecule inhibitor targeting the SRC Family of Kinases (SFK), including SRC and YES1, which plays a critical role in cancer progression. The unique mechanism of NXP900 involves inhibiting both the catalytic and scaffolding functions of the SRC kinase, resulting in a comprehensive shutdown of the signaling pathway.

The first presentation, titled "NXP900, a novel YES1/SRC kinase inhibitor in phase 1 dose escalation, demonstrates potent synergy with ALK inhibitors in ALK resistant cell lines," will be delivered by Asier Unciti-Broceta from the University of Edinburgh, Scotland. This poster session will take place on October 24, 2024, from 09:00 to 17:30 CET. The presentation will discuss the synergistic effects of NXP900 when used in combination with ALK inhibitors in cell lines resistant to ALK inhibitors.

The second presentation, "A multi-omics approach to identify biomarkers of response to the novel and selective SRC/YES1 inhibitor NXP900," will be presented by Ben King, also from the University of Edinburgh, Scotland. This session is scheduled for October 25, 2024, from 09:00 to 15:00 CET. The focus of this poster session will be on identifying biomarkers that can help predict the response to NXP900, using a comprehensive multi-omics approach.

Nuvectis Pharma is also developing another clinical-stage drug candidate, NXP800. This oral small molecule GCN2 activator is currently in a Phase 1b clinical trial for the treatment of platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also under investigation in a clinical trial for cholangiocarcinoma. The U.S. Food and Drug Administration has granted Fast Track Designation to the NXP800 development program for treating platinum-resistant, ARID1a-mutated ovarian carcinoma. Additionally, it has received Orphan Drug Designations for treating cholangiocarcinoma and ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.

NXP900 is currently undergoing a Phase 1a dose escalation study to determine its safety and efficacy in humans. This study aims to establish the optimal dose for subsequent phases of clinical trials and to further explore the drug's potential in treating various cancers.

Nuvectis Pharma continues to advance its research and development efforts to bring innovative cancer therapies to patients with significant unmet medical needs. The upcoming presentations at the AACR-NCI-EORTC conference will provide valuable insights into the potential of NXP900 as a novel therapeutic option in oncology.